1279026-33-3

Basic information

• Product Name: N-methyl-N-{3-[2-(piperidin-1-yl)pyrimidin-5-yl]benzyl}glycinamide
• Synonyms: N-methyl-N-{3-[2-(piperidin-1-yl)pyrimidin-5-yl]benzyl}glycinamide
• CAS NO: 1279026-33-3
• Molecular Weight: 339.44
• Mol File: 1279026-33-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-methyl-N-{3-[2-(piperidin-1-yl)pyrimidin-5-yl]benzyl}glycinamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-N-{3-[2-(piperidin-1-yl)pyrimidin-5-yl]benzyl}glycinamide(1279026-33-3)
• EPA Substance Registry System: N-methyl-N-{3-[2-(piperidin-1-yl)pyrimidin-5-yl]benzyl}glycinamide(1279026-33-3)

Safety Data

• Hazardous Substances Data: 1279026-33-3(Hazardous Substances Data)

Upstream product

• 1015242-08-6 2-(piperidin-1-yl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyrimidine 
• 1279027-03-0 tert-butyl {2-[(3-bromobenzyl)(methyl)amino]-2-oxoethyl}carbamate 

Relevant articles and documents

GLYCINE COMPOUND

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.